デフォルト表紙
市場調査レポート
商品コード
1441166

凍結乾燥注射剤の世界市場規模、シェア、成長分析、薬剤別、適応症別-産業予測、2023~2030年

Global Lyophilized Injectable Drugs Market Size, Share, Growth Analysis, By Drug(Anti-infective, Anti-neoplastic), By Indication(Autoimmune diseases, Respiratory diseases) - Industry Forecast 2023-2030

出版日: | 発行: SkyQuest | ページ情報: 英文 157 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
凍結乾燥注射剤の世界市場規模、シェア、成長分析、薬剤別、適応症別-産業予測、2023~2030年
出版日: 2024年02月19日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

凍結乾燥注射剤の世界市場規模は、2022年に30億9,000万米ドルと評価され、2023年の33億9,000万米ドルから2031年には54億4,000万米ドルへと、予測期間中(2024~2031年)のCAGRは6.5%で成長する展望です。

凍結乾燥注射薬の世界市場は、注射に適した安定した粉末状の製剤を作るために凍結乾燥を行った医薬品を提供しています。このプロセスは、水分を除去することで医薬品の保存期間を延長し、保管や輸送を容易にします。この市場は、汚染リスクの低減と薬効の維持という利点により、大きな成長を遂げています。凍結乾燥注射剤は、感染症、腫瘍、自己免疫疾患など、様々な治療セグメントに応用されています。製造工程では、薬液を凍結させ、次いで真空下で昇華させて乾燥粉末を得る。市場の主要促進要因は、特に生物製剤や分解しやすい複雑な分子に対する、より安定した製剤の需要です。医療プロバイダーは、保存期間が延長され無駄が減ることから、これらの薬剤を好んで使用しています。さらに、凍結乾燥された医薬品は、緊急事態や、資源が限られているために冷蔵設備を欠く環境において利点を提供します。とはいえ、特殊な装置の必要性や製造コストの上昇といった課題も存在します。凍結乾燥薬剤の再構成におけるミスは、薬剤の有効性と患者の安全性に影響を及ぼす可能性があり、適切なトレイニングが必要となり、時間と資源を浪費する可能性があります。このような障害にもかかわらず、凍結乾燥技術の継続的な進歩、新たな治療領域における研究の拡大、薬剤の安定性を高める取り組みにより、市場の成長は維持されると予想されます。

目次

エグゼクティブサマリー

  • 市場概要
  • 運命の輪

調査手法

  • 情報調達
  • セカンダリとプライマリデータソース
  • 市場規模の推定
  • 市場の前提条件と制限

親市場の分析

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題

主要市場の考察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 貿易分析
  • スタートアップ分析
  • 原材料の分析
  • イノベーションマトリクス
  • パイプライン製品の分析
  • マクロ経済指標
  • 主要投資の分析
  • 主要成功要因
  • 競合の程度

市場力学と展望

  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題
  • 規制情勢
  • ポーターの分析
  • 将来の混乱についての特別な考察

凍結乾燥注射剤の世界市場:薬物別

  • 市場概要
  • 抗感染症
  • 抗腫瘍性
  • 抗凝固剤
  • ホルモン
  • 抗不整脈薬
  • その他

凍結乾燥注射剤の世界市場:適応症別

  • 市場概要
  • 自己免疫疾患
  • 呼吸器疾患
  • 胃腸障害
  • 腫瘍学
  • 心血管疾患
  • 感染症
  • 代謝障害
  • その他

凍結乾燥注射剤の世界市場規模:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他の欧州地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他のラテンアメリカ地域
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ地域

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2021年)
  • 主要市場企業が採用した戦略
  • 主要成功戦略
  • 市場における最近の活動
  • 主要企業の市場シェア(2021年)

主要企業プロファイル

  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Amgen Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Biogen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Celgene Corporation
  • Novo Nordisk A/S
  • Vertex Pharmaceuticals Incorporated
  • Takeda Pharmaceutical Company Limited
目次
Product Code: SQMIG35B2145

Global Lyophilized Injectable Drugs Market size was valued at USD 3.09 Billion in 2022 and is poised to grow from USD 3.39 Billion in 2023 to USD 5.44 Billion by 2031, at a CAGR of 6.5% during the forecast period (2024-2031).

The global market for lyophilized injectable drugs offers pharmaceutical products that have undergone freeze-drying to create stable, powder-like formulations suitable for injection. This process extends the shelf life of medications by removing water content, facilitating convenient storage and transportation. The market has experienced significant growth due to its benefits in reducing contamination risk and preserving drug efficacy. Lyophilized injectable drugs find application across various therapeutic areas such as infectious diseases, oncology, autoimmune disorders, and more. The manufacturing process involves freezing the drug solution, followed by sublimation under vacuum to obtain a dry powder that can be reconstituted into liquid form using a suitable solvent prior to administration. A key driver for the market is the demand for more stable formulations, particularly for biologics and complex molecules prone to degradation. Healthcare providers favor these drugs due to their extended shelf life, reducing wastage. Additionally, lyophilized drugs offer advantages in emergency situations and environments lacking refrigeration due to limited resources. Nevertheless, challenges such as the need for specialized equipment and higher production costs exist. Errors in reconstituting lyophilized drugs can affect medication effectiveness and patient safety, necessitating proper training and potentially wasting time and resources. Despite these obstacles, ongoing advancements in lyophilization techniques, expanding research in new therapeutic areas, and efforts to enhance drug stability are expected to sustain market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lyophilized Injectable Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Lyophilized Injectable Drugs Market Segmental Analysis

The global lyophilized injectable drugs market is segmented by Drug, Indication, Delivery, Packaging, Distribution Channel, and Region. Based on Drug the market is segmented as, Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Antiarrhythmic, Others. Based on Indication the market is segmented as, autoimmune diseases, respiratory diseases, gastrointestinal disorders, Oncology, Cardiovascular diseases, Infectious diseases, Metabolic disorders, others. Based on Delivery the market is segmented as, Prefilled diluent syringes, Multi-step devices. Based on Packaging the market is segmented as, Vials, Cartridges, and Prefilled devices. Based on Distribution Channel the market is segmented as, Hospital pharmacy, Retail pharmacy, and online pharmacy. Regional the market is segmented as, North America, Asia Pacific, Latin America, and Middle East & Africa (MEA).

Drivers of the Global Lyophilized Injectable Drugs Market

The rising demand for lyophilized injectable drugs is driven by the growing use of peptides, biologics, and other complex molecules in therapies. These drugs often require stable formulations to preserve their efficacy, given their delicate nature.

The process of lyophilization extends the shelf life of therapeutic drugs by removing water content and improving drug stability. Healthcare providers and pharmaceutical manufacturers seeking products with extended storage periods are particularly drawn to this advantageous characteristic.

Restraints in the Global Lyophilized Injectable Drugs Market

The rising demand for lyophilized injectable drugs is driven by the growing use of peptides, biologics, and other complex molecules in therapies. These drugs often require stable formulations to preserve their efficacy, given their delicate nature.

The process of lyophilization extends the shelf life of therapeutic drugs by removing water content and improving drug stability. Healthcare providers and pharmaceutical manufacturers seeking products with extended storage periods are particularly drawn to this advantageous characteristic.

Market Trends of the Global Lyophilized Injectable Drugs Market

Increase in Biologics and Complex Molecules: The market witnessed a rise in the development and utilization of peptides, biologics, and other complex molecules across different therapeutic areas. Lyophilization plays a crucial role in preserving the stability of these fragile molecules, ensuring their efficacy upon reconstitution, a critical factor in the industry.

Innovations in Drug Delivery: Technological advancements have led to improvements in drug delivery systems for lyophilized injectables. This includes the development of user-friendly devices and reconstitution mechanisms, enhancing patient convenience.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Lyophilized Injectable Drugs Market by Drug

  • Market Overview
  • Anti-infective
  • Anti-neoplastic
  • Anticoagulant
  • Hormones
  • Antiarrhythmic
  • Others

Global Lyophilized Injectable Drugs Market by Indication

  • Market Overview
  • Autoimmune diseases
  • Respiratory diseases
  • Gastrointestinal disorders
  • Oncology
  • Cardiovascular diseases
  • Infectious diseases
  • Metabolic disorders
  • and Others

Global Lyophilized Injectable Drugs Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca PLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk A/S
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vertex Pharmaceuticals Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments